ArticleIDCases2026
Amikacin bladder instillation as prophylaxis for recurrent urinary tract infections in a child with neurogenic bladder: A case report.
Article in IDCases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Recurrent symptomatic urinary tract infections (rUTIs) in pediatric patients with neurogenic bladder and chronic kidney disease can be particularly difficult to manage with an appropriate prophylaxis and treatment, especially when caused by multidrug-resistant organisms. Intravesical aminoglycoside instillation may provide a safe renal-sparing prophylactic option. Case presentation: A 9-year-old female with neurogenic bladder due to voiding dysfunction, stage 2 chronic kidney disease and bilateral hydronephrosis, who presented with high-grade fever, flank pain and vomiting. She had had 3 hospitalizations for multi-drug resistant urinary tract infections (MDR-UTIs) in the past 6 months, despite previous use of oral prophylaxis. Initially, she was receiving sulfamethoxazole/trimethoprim, then switched to nitrofurantoin for 6 months. The urine culture grew Klebsiella pneumoniae (ESBL-producing), with sensitivity to amikacin, meropenem and imipenem. The patient was treated with intravenous meropenem for 14 days, with both clinical and microbiological resolution. To minimize the chance of recurrence, a prophylaxis regimen started as intravesical amikacin instillation (250 mg in 50 mL normal saline) via self-intermittent catheterization - daily for 2 weeks, alternate days for 10 weeks, and finally twice weekly for 12 weeks. At 2-week follow-up visit, she was additionally started on prophylactic sulfamethoxazole/trimethoprim. Approximately 18 months follow-up after discharge, the patient remained asymptomatic with no further UTIs. Conclusion: This case report provides useful information on effective long-term prophylaxis of multi-drug resistant recurrent urinary tract infection or rUTI, using intravesical amikacin in a child with neurogenic bladder and renal injury. Utilizing specific protocols for dosage standardization and prospective studies to assess the safety and effectiveness would be beneficial.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.